ID

41011

Description

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01485991

Link

https://clinicaltrials.gov/show/NCT01485991

Keywords

Versions (1)
  1. 6/11/20 6/11/20 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

June 11, 2020

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Hepatitis C NCT01485991

English

Eligibility Hepatitis C NCT01485991

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patient must have had a liver biopsy before screening (or between the screening and baseline visit), unless patient cannot undergo such a procedure or has evidence of portal hypertension not associated with cirrhosis. for patients who had a liver biopsy performed more than 2 years prior to screening or without a biopsy (because of a contraindication or portal hypertension), a non-invasive staging assessment needs to be available. non-invasive staging assessments include fibroscan, mr-elastography, or fibrotest/fibrosure and must not be older than 6 months prior to screening
Description

Biopsy of liver | Fibroscan | MR Elastography | FibroTest Score Measurement | Fibrosure | Age

Data type

boolean

Alias
UMLS CUI [1]
C0193388
UMLS CUI [2]
C4522043
UMLS CUI [3]
C1518156
UMLS CUI [4]
C3642160
UMLS CUI [5]
C1955263
UMLS CUI [6]
C0001779
chronicity of hepatitis c virus (hcv) infection, as confirmed by one or both of the following: presence of anti-hcv antibody and/or hcv ribonucleic acid (rna) at least 6 months prior to the screening visit and/or presence of fibrosis on biopsy
Description

Hepatitis C, Chronic | Hepatitis C Antibodies Present | Hepatitis C virus RNA Present | Fibrosis Biopsy

Data type

boolean

Alias
UMLS CUI [1]
C0524910
UMLS CUI [2,1]
C0166049
UMLS CUI [2,2]
C0150312
UMLS CUI [3,1]
C0369335
UMLS CUI [3,2]
C0150312
UMLS CUI [4,1]
C0016059
UMLS CUI [4,2]
C0005558
genotype 1 hcv infection with plasma hcv rna of >10,000 iu/ml (both confirmed at screening)
Description

Hepatitis C Genotype | Plasma Hepatitis C virus RNA assay

Data type

boolean

Alias
UMLS CUI [1,1]
C0019196
UMLS CUI [1,2]
C1533728
UMLS CUI [2,1]
C0032105
UMLS CUI [2,2]
C1272251
patient must have had at least 1 documented previous course of treatment with peginfα-2a or peginfα-2b in combination with ribavirin (rbv) (at least 12 weeks for null responder and 20 weeks for partial responder)
Description

Course Previous Quantity | Combined Modality Therapy | peginterferon alfa-2a | peginterferon alfa-2b | Ribavirin | Therapy non-responder | Partial responder to therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0750729
UMLS CUI [1,2]
C0205156
UMLS CUI [1,3]
C1265611
UMLS CUI [2]
C0009429
UMLS CUI [3]
C0391001
UMLS CUI [4]
C0796545
UMLS CUI [5]
C0035525
UMLS CUI [6]
C0919875
UMLS CUI [7]
C1740822
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
hepatic decompensation (impaired functioning of the liver), as indicated by significant laboratory abnormalities or other active diseases
Description

Hepatic decompensation | Relationship LABORATORY ABNORMALITIES | Relationship Comorbidity

Data type

boolean

Alias
UMLS CUI [1]
C1394798
UMLS CUI [2,1]
C0439849
UMLS CUI [2,2]
C1853129
UMLS CUI [3,1]
C0439849
UMLS CUI [3,2]
C0009488
infection with human immunodeficiency virus (hiv) or non genotype 1 hepatitis c
Description

HIV Infection | Hepatitis C Genotype

Data type

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2,1]
C0019196
UMLS CUI [2,2]
C1533728
liver disease not related to hepatitis c infection
Description

Liver diseases Independent of Hepatitis C

Data type

boolean

Alias
UMLS CUI [1,1]
C0023895
UMLS CUI [1,2]
C0332291
UMLS CUI [1,3]
C0019196
previous chronic hepatitis c treatment, other than pegifn and rbv
Description

Prior Therapy Chronic Hepatitis C | Exception PEGINTERFERON | Exception Ribavirin

Data type

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0524910
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0982327
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0035525
Back to the top of the page

Similar models

Eligibility Hepatitis C NCT01485991

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Biopsy of liver | Fibroscan | MR Elastography | FibroTest Score Measurement | Fibrosure | Age
Item
patient must have had a liver biopsy before screening (or between the screening and baseline visit), unless patient cannot undergo such a procedure or has evidence of portal hypertension not associated with cirrhosis. for patients who had a liver biopsy performed more than 2 years prior to screening or without a biopsy (because of a contraindication or portal hypertension), a non-invasive staging assessment needs to be available. non-invasive staging assessments include fibroscan, mr-elastography, or fibrotest/fibrosure and must not be older than 6 months prior to screening
boolean
C0193388 (UMLS CUI [1])
C4522043 (UMLS CUI [2])
C1518156 (UMLS CUI [3])
C3642160 (UMLS CUI [4])
C1955263 (UMLS CUI [5])
C0001779 (UMLS CUI [6])
Hepatitis C, Chronic | Hepatitis C Antibodies Present | Hepatitis C virus RNA Present | Fibrosis Biopsy
Item
chronicity of hepatitis c virus (hcv) infection, as confirmed by one or both of the following: presence of anti-hcv antibody and/or hcv ribonucleic acid (rna) at least 6 months prior to the screening visit and/or presence of fibrosis on biopsy
boolean
C0524910 (UMLS CUI [1])
C0166049 (UMLS CUI [2,1])
C0150312 (UMLS CUI [2,2])
C0369335 (UMLS CUI [3,1])
C0150312 (UMLS CUI [3,2])
C0016059 (UMLS CUI [4,1])
C0005558 (UMLS CUI [4,2])
Hepatitis C Genotype | Plasma Hepatitis C virus RNA assay
Item
genotype 1 hcv infection with plasma hcv rna of >10,000 iu/ml (both confirmed at screening)
boolean
C0019196 (UMLS CUI [1,1])
C1533728 (UMLS CUI [1,2])
C0032105 (UMLS CUI [2,1])
C1272251 (UMLS CUI [2,2])
Course Previous Quantity | Combined Modality Therapy | peginterferon alfa-2a | peginterferon alfa-2b | Ribavirin | Therapy non-responder | Partial responder to therapy
Item
patient must have had at least 1 documented previous course of treatment with peginfα-2a or peginfα-2b in combination with ribavirin (rbv) (at least 12 weeks for null responder and 20 weeks for partial responder)
boolean
C0750729 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0009429 (UMLS CUI [2])
C0391001 (UMLS CUI [3])
C0796545 (UMLS CUI [4])
C0035525 (UMLS CUI [5])
C0919875 (UMLS CUI [6])
C1740822 (UMLS CUI [7])
Item Group
C0680251 (UMLS CUI)
Hepatic decompensation | Relationship LABORATORY ABNORMALITIES | Relationship Comorbidity
Item
hepatic decompensation (impaired functioning of the liver), as indicated by significant laboratory abnormalities or other active diseases
boolean
C1394798 (UMLS CUI [1])
C0439849 (UMLS CUI [2,1])
C1853129 (UMLS CUI [2,2])
C0439849 (UMLS CUI [3,1])
C0009488 (UMLS CUI [3,2])
HIV Infection | Hepatitis C Genotype
Item
infection with human immunodeficiency virus (hiv) or non genotype 1 hepatitis c
boolean
C0019693 (UMLS CUI [1])
C0019196 (UMLS CUI [2,1])
C1533728 (UMLS CUI [2,2])
Liver diseases Independent of Hepatitis C
Item
liver disease not related to hepatitis c infection
boolean
C0023895 (UMLS CUI [1,1])
C0332291 (UMLS CUI [1,2])
C0019196 (UMLS CUI [1,3])
Prior Therapy Chronic Hepatitis C | Exception PEGINTERFERON | Exception Ribavirin
Item
previous chronic hepatitis c treatment, other than pegifn and rbv
boolean
C1514463 (UMLS CUI [1,1])
C0524910 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0982327 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0035525 (UMLS CUI [3,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial